Shares

18 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2022

Feb 08, 2023

SELL
$68.48 - $81.09 $259,813 - $307,655
-3,794 Reduced 42.09%
5,221 $375,000
Q3 2022

Nov 15, 2022

BUY
$0.13 - $76.84 $637 - $376,516
4,900 Added 119.08%
9,015 $641,000
Q2 2022

Nov 15, 2022

SELL
$72.62 - $79.98 $9,004 - $9,917
-124 Reduced 2.93%
4,115 $317,000
Q2 2022

Aug 05, 2022

BUY
$72.62 - $79.98 $9,004 - $9,917
124 Added 3.01%
4,239 $326,000
Q4 2021

May 20, 2022

SELL
$53.63 - $62.52 $17,000 - $19,818
-317 Reduced 7.15%
4,115 $257,000
Q4 2021

Feb 14, 2022

BUY
$53.63 - $62.52 $17,000 - $19,818
317 Added 7.7%
4,432 $276,000
Q3 2021

May 20, 2022

SELL
$59.17 - $69.31 $10,058 - $11,782
-170 Reduced 3.97%
4,115 $243,000
Q3 2021

Nov 15, 2021

BUY
$59.17 - $69.31 $10,058 - $11,782
170 Added 4.13%
4,285 $254,000
Q2 2021

Aug 10, 2021

SELL
$61.91 - $67.42 $36,279 - $39,508
-586 Reduced 12.47%
4,115 $275,000
Q1 2021

May 17, 2021

SELL
$59.34 - $66.74 $1,958 - $2,202
-33 Reduced 0.7%
4,701 $297,000
Q3 2020

Nov 13, 2020

SELL
$57.43 - $63.64 $31,184 - $34,556
-543 Reduced 10.29%
4,734 $285,000
Q2 2020

Aug 11, 2020

BUY
$54.82 - $64.09 $8,880 - $10,382
162 Added 3.17%
5,277 $310,000
Q1 2020

May 14, 2020

BUY
$46.4 - $67.43 $37,769 - $54,888
814 Added 18.93%
5,115 $285,000
Q4 2019

Feb 13, 2020

BUY
$49.21 - $64.19 $211,652 - $276,081
4,301 New
4,301 $276,000
Q1 2019

May 08, 2019

SELL
$45.12 - $53.8 $189,052 - $225,422
-4,190 Closed
0 $0
Q2 2018

Aug 03, 2018

SELL
$50.53 - $62.98 $18,746 - $23,365
-371 Reduced 8.13%
4,190 $232,000
Q3 2017

Nov 13, 2017

BUY
$55.23 - $63.74 $27,449 - $31,678
497 Added 12.23%
4,561 $291,000
Q1 2017

Aug 14, 2017

BUY
N/A
4,064
4,064 $221,000

Others Institutions Holding BMY

About BRISTOL MYERS SQUIBB CO


  • Ticker BMY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,126,160,000
  • Market Cap $113B
  • Description
  • Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...
More about BMY
Track This Portfolio

Track Coastal Bridge Advisors, LLC Portfolio

Follow Coastal Bridge Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Coastal Bridge Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Coastal Bridge Advisors, LLC with notifications on news.